Theriva Biologics, Inc.

TOVX

US87164U4094

Biotechnology & Medical Research

Market Closed - Nyse Other stock markets 04:00:00 2024-04-19 pm EDT			5-day change	1st Jan Change
0.4152 ^USD	-7.32%		-7.63%	-3.46%

Mar. 25	Transcript : Theriva Biologics, Inc., 2023 Earnings Call, Mar 25, 2024
Mar. 25	Theriva Biologics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Theriva Biologics, Inc. announced that it has received $3 million in funding from MSD Partners, L.P.

July 28, 2022

On July 29, 2022, Synthetic Biologics, Inc. closed the transaction.

Latest news about Theriva Biologics, Inc.

Transcript : Theriva Biologics, Inc., 2023 Earnings Call, Mar 25, 2024	Mar. 25
Theriva Biologics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 25	CI
North American Morning Briefing : Tech in Focus on -2-	Mar. 25	DJ
Theriva Biologics Announces Positive Recommendation from the Independent Data Monitoring Committee of VIRAGE, the Phase 2b Clinical Trial of VCN-01 in Combination with Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma	Feb. 07	CI
Transcript : Theriva Biologics, Inc., Q3 2023 Earnings Call, Nov 13, 2023	Nov. 13
Theriva Biologics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
North American Morning Briefing : Stock Futures -2-	Nov. 13	DJ
Theriva?? Biologics and Sant Joan de Deu-Bar Barcelona Children's Hospital Advance Strategic Collaboration to Explore the Combination of VCN-01 with Topoisomerase Inhibitors to Treat Cancer	Nov. 02	CI
Transcript : Theriva Biologics, Inc. - Special Call	23-10-23
Theriva? Biologics Presents Survival Outcomes Data from Phase 1 Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck at ESMO Congress 2023	23-10-23	CI
Theriva Biologics, Inc. Announces Presentation at Esmo Congress 2023 Featuring Survival Outcomes in Phase 1 Study Evaluating Vcn-01 in Combination with Durvalumab in Patients with Recurrent/ Metastatic Squamous Cell Carcinoma of the Head and Neck	23-10-17	CI
Theriva Biologics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-08	CI
Transcript : Theriva Biologics, Inc., Q2 2023 Earnings Call, Aug 08, 2023	23-08-08
Theriva Biologics Announces Key Progress in Virage, an Ongoing, Multinational Phase 2B Trial of VCN-01 in Combination with Chemotherapy in Pancreatic Ductal Adenocarcinoma	23-08-02	CI
Potential US Curbs on AI Chip Exports to China Drag Sentiment, Driving Premarket Losses for US Equity Futures	23-06-28	MT
Top Premarket Gainers	23-06-28	MT
Theriva Gets Orphan Drug Designation for VCN-01 to Treat Pancreatic Cancer	23-06-27	DJ
Theriva Biologics Says US FDA Grants Orphan Drug Designation to VCN-01 for Pancreatic Cancer Treatment; Shares Surge	23-06-27	MT
Theriva Biologics Appoints Ramon Alemany as Senior VP of Discovery	23-05-23	CI
Transcript : Theriva Biologics, Inc., Q1 2023 Earnings Call, May 11, 2023	23-05-11
Theriva Biologics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI
Transcript : Theriva Biologics, Inc., Q4 2022 Earnings Call, Mar 30, 2023	23-03-30
Theriva Biologics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-30	CI
Theriva Biologics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-30	CI
North American Morning Briefing : Stock Futures -3-	23-03-27	DJ

Theriva Biologics, Inc. is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. It is advancing a new oncolytic adenovirus platform. Its candidates are VCN-01, SYN-004 (ribaxamase) and SYN-020. VCN-01 is an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade the tumor stroma barrier that serves as a significant physical and immunosuppressive barrier to cancer treatment. SYN-004 (ribaxamase) is designed to degrade certain commonly used intravenous beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent microbiome damage. SYN-020 is a recombinant oral formulation of the enzyme intestinal alkaline phosphatase produced under current good manufacturing practice conditions and intended to treat both local GI and systemic diseases. Its research programs include VCN-11 Albumin Shield Technology and SYN-006, SYN-007, other oncolytic virus.

Sector

Biotechnology & Medical Research

Calendar

2024-05-07 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.448 USD

Average target price

4.5 USD

Spread / Average Target

+904.46%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
THERIVA BIOLOGICS, INC.	-3.46%	7.68M
VERTEX PHARMACEUTICALS INCORPORATED	-3.10%	102B
REGENERON PHARMACEUTICALS, INC.	+2.11%	96.07B
ARGENX SE	-1.80%	21.66B
BIONTECH SE	-17.75%	20.77B
GENMAB A/S	-6.91%	18.53B
WUXI APPTEC CO., LTD.	-42.00%	16.91B
BEIGENE, LTD.	-28.19%	13.79B
NEUROCRINE BIOSCIENCES, INC.	+0.18%	13.33B
SAREPTA THERAPEUTICS, INC.	+19.90%	10.94B

Bio Therapeutic Drugs